Candel Therapeutics Valuation
| CADL Stock | USD 5.92 0.05 0.85% |
At this time, the firm appears to be undervalued. Candel Therapeutics shows a prevailing Real Value of $8.81 per share. The current price of the firm is $5.92. Our model approximates the value of Candel Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.7, shares owned by insiders of 16.75 %, and Current Valuation of 245.79 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Candel Therapeutics' valuation include:
Price Book 3.9945 | Enterprise Value | Enterprise Value Ebitda (0.01) | Price Sales 436.4156 | Forward PE 43.4783 |
Undervalued
Today
Please note that Candel Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Candel Therapeutics is based on 3 months time horizon. Increasing Candel Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Candel stock is determined by what a typical buyer is willing to pay for full or partial control of Candel Therapeutics. Since Candel Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Candel Stock. However, Candel Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.92 | Real 8.81 | Target 18.63 | Hype 5.92 | Naive 5.62 |
The intrinsic value of Candel Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Candel Therapeutics' stock price.
Estimating the potential upside or downside of Candel Therapeutics helps investors to forecast how Candel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Candel Therapeutics more accurately as focusing exclusively on Candel Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Candel Therapeutics' intrinsic value based on its ongoing forecasts of Candel Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Candel Therapeutics' closest peers.
Candel Therapeutics Cash |
|
Candel Therapeutics Total Value Analysis
Candel Therapeutics is currently forecasted to have valuation of 245.79 M with market capitalization of 322.25 M, debt of 13.47 M, and cash on hands of 86.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Candel Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
245.79 M | 322.25 M | 13.47 M | 86.78 M |
Candel Therapeutics Asset Utilization
One of the ways to look at asset utilization of Candel is to check how much profit was generated for every dollar of assets it reports. Candel Therapeutics shows a negative utilization of assets of -0.43 percent, losing $0.004325 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Candel Therapeutics shows how discouraging it operates for each dollar spent on its assets.Candel Therapeutics Profitability Analysis
Based on Candel Therapeutics' profitability indicators, Candel Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Candel Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -4.8 M | Current Value -11.3 M | Quarterly Volatility 6.5 M |
For Candel Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Candel Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Candel Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Candel Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Candel Therapeutics over time as well as its relative position and ranking within its peers.
Candel Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Candel Therapeutics is estimated to be -0.15 with future projections ranging from a low of -0.15 to a high of -0.15. Candel Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.56. Please be aware that the consensus of earnings estimates for Candel Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Candel Therapeutics Earnings Estimation Breakdown
The calculation of Candel Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Candel Therapeutics is estimated to be -0.15 with the future projection ranging from a low of -0.15 to a high of -0.15. Please be aware that this consensus of annual earnings estimates for Candel Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.15 Lowest | Expected EPS | -0.15 Highest |
Candel Therapeutics Earnings Projection Consensus
Suppose the current estimates of Candel Therapeutics' value are higher than the current market price of the Candel Therapeutics stock. In this case, investors may conclude that Candel Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Candel Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 8 | 63.3% | 0.0 | -0.15 | -0.56 |
Candel Therapeutics Ownership Allocation
Candel Therapeutics holds a total of 54.9 Million outstanding shares. 30% of Candel Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Candel Therapeutics Profitability Analysis
Net Loss for the year was (55.18 M) with loss before overhead, payroll, taxes, and interest of (23.07 M).About Candel Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Candel Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Candel Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Candel Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Candel Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Candel Therapeutics. We calculate exposure to Candel Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Candel Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -891 K | -935.5 K | |
| Pretax Profit Margin | (172.90) | (181.55) | |
| Operating Profit Margin | (319.44) | (335.41) | |
| Net Loss | (172.90) | (181.55) | |
| Gross Profit Margin | (133.11) | (139.77) |
Candel Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Candel Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 31.7 M | |
| Forward Price Earnings | 43.4783 |
Candel Therapeutics Current Valuation Indicators
Candel Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Candel Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Candel Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Candel Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Candel Therapeutics' worth.When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. Projected growth potential of Candel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Candel Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Candel Therapeutics requires distinguishing between market price and book value, where the latter reflects Candel's accounting equity. The concept of intrinsic value - what Candel Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Candel Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Candel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Candel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Candel Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.